Work

Supplementary Table S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

Year: 2025
Type: supplementary-materials
Abstract: Table S2 shows the p-values for overall survival and relapse-free survival across the three randomized studies.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4415212126
Cites:
Cited by:
Related to: 10